Suppr超能文献

[临床实践中的免疫学。VI. 当前的免疫抑制药物]

[Immunology in clinical practice. VI. Current immunosuppressive drugs].

作者信息

ten Berge R J, Schellekens P T

机构信息

Academisch Medisch Centrum, afd. Inwendige Geneeskunde, Amsterdam.

出版信息

Ned Tijdschr Geneeskd. 1997 Nov 22;141(47):2289-92.

PMID:9550813
Abstract

Immunosuppressive drugs are agents capable of modulating at least one type of immune response in vivo at doses with tolerable side-effects. Classical immunosuppressive drugs include corticosteroids, azathioprine, cyclophosphamide, methotrexate and cyclosporine. In the past two years tacrolimus and mycophenolate mofetil were registered as immunosuppressive drugs. Tacrolimus interferes with the calcium-dependent signal transduction of T-lymphocytes. Mycophenolate mofetil is an inhibitor of purine synthesis by inhibition of the enzyme inosine monophosphate dehydrogenase. Both tacrolimus and mycophenolate mofetil have proven efficacy in both prevention and treatment of acute allograft rejection. The new drugs are stronger than the classical ones but do not cause more adverse reactions. The value in clinical medicine of some new, promising immunosuppressive drugs, i.e. sirolimus (rapamycin), mizoribine, brequinar and leflunomide remains to be proven.

摘要

免疫抑制药物是一类能够在体内以副作用可耐受的剂量调节至少一种免疫反应的药物。传统的免疫抑制药物包括皮质类固醇、硫唑嘌呤、环磷酰胺、甲氨蝶呤和环孢素。在过去两年中,他克莫司和霉酚酸酯被注册为免疫抑制药物。他克莫司干扰T淋巴细胞的钙依赖性信号转导。霉酚酸酯通过抑制肌苷单磷酸脱氢酶来抑制嘌呤合成。他克莫司和霉酚酸酯在预防和治疗急性移植物排斥反应方面均已证明有效。这些新药比传统药物更强,但不会引起更多不良反应。一些有前景的新型免疫抑制药物,即西罗莫司(雷帕霉素)、咪唑立宾、布喹那和来氟米特在临床医学中的价值仍有待证实。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验